New MolecuLight data from over 2,000 patients will be presented at SAWC Fall 2022 ...

15.10.2022 – 22:46

MolecuLight Inc.

TORONTO and LAS VEGAS, April 20 / PRNewswire /

MolecuLight Wound Imaging Platform Offers New Clinical Information Demonstrating Better Clinical Decision Making and Better Patient Outcomes

MolecuLight Inc., leader in point-of-care fluorescence imaging for real-time detection of high bacterial load in wounds, announces new MolecuLight data from over 2,000 patients onwards to the Advanced Wound Care Symposium (SAWC) Fall 2022 to introduce. The data will be presented in a combination of seven clinical posters and three clinical conferences and workshops. The international conference, which will be held October 13-16, 2022 in Las Vegas, Nevada, is one of the largest multidisciplinary gatherings of wound care professionals in the world.

“We are thrilled that our customers are presenting the results of more than 2,000 patients screened with the MolecuLight Imaging Platform at SAWC Fall this week,” said Anil Amlani, CEO of MolecuLight. “This amount of clinical evidence is unprecedented for a wound imaging device and illustrates the significant benefits that MolecuLight me: X- And DX devices across the range of care facilities. I am particularly proud of the amazing improvement in clinical outcomes in vulnerable patient populations when clinicians use MolecuLight devices. This includes seniors and people with disabilities in long-term care and skilled care settings, as well as studies using MolecuLight in patient populations with different skin pigmentations. “

“My organization serves wound care for long-term care and specialist care in several states. The MolecuLight process is standard practice for our wound care professionals because it provides us with unmatched information on decision making, “said Martha R. Kelso, CEO of Wound Care Plus, LLC.” I will share our documented and real-world insights. at SAWC To present the results of using MolecuLight, including improved wound healing rates and reduced use of antibiotics, as well as a significant reduction in patients with severe infection-related complications (cellulitis, sepsis, osteomyelitis, or hospitalizations related to wounds) without increased systemic use of antibiotics. Improving outcomes for this vulnerable population through the use of this imaging tool is extremely impressive and much needed. “

A post on MolecuLight titled Closing the gap on racial disparities in diagnosing chronic wound infections: the worrying trend involving skin pigmentation and the role of fluorescence imaging by dr. Jonathan Johnson, MD MBA CWSP, Medical Director at Comprehensive Wound Care Services and Capital Aesthetic & Laser Center, Washington DC, was selected as one of four highest scoring abstracts. This is the fifth consecutive SWAC meeting in which an abstract on improving clinical decision making and patient outcomes through the use of MolecuLight bacterial detection technology has received this award. “There are known to be different wound healing outcomes and amputation rates in patients with low and high skin pigmentation. Fluorescence imaging with MolecuLight allowed clinicians to identify more at-risk or clinically infected wounds in all skin tones than standard clinical evaluation, “says Dr. Johnson Sensitivity for bacterial strain detection using signs alone and standard clinical symptoms was only 3% This value increased 12 times when MolecuLight was used These results are impressive and a good indication of the ability of this modality to perform Raising the bar for diagnostic imaging in different race patient populations , which supports our efforts to identify and reduce inequalities that impact health outcomes. “

To die clinical presentation and poster with MolecuLight i: X And DX the SAWC Fall 2022 are as follows:

a) CLINICAL PRESENTATIONS

Closing the gap on racial disparities in diagnosing chronic wound infections: the worrying trend involving skin pigmentation and the role of fluorescence imaging Dr. Jonathan Johnson, MD, MBA, CWSP Advanced Clinical Practice & Emerging Research (SAWC Oral Abstracts), Samstag, 15. October 2022, 9:00 – 10:00 Uhr, Julius 1-4

Breaking prejudice with wound imaging: racial disparities and the quality of the vulnerable population of Cura Presenter Dot Weir, RN, CWON, CWS and presenters Martha Kelso, RN, HBOT, Dr. Jonathan Johnson, MD, MBA, CWSP, Dr. Charles A. Andersen, MD, FACS, MAPWCA and Dr. Alton Johnson Jr., DPM, FACPM, DABPM, CWSP Innovation Theater Laboratory, Sunday 16 October 2022, 7:45 am – 9:00 am, Milan VII-VIII

Enlighten bold ideas in wound care Bacterial Burden Imaging in Patients with Complex Wounds: Analysis of Healing Outcomes, Infections, and Life-threatening Complications Martha Kelso, CEO, Wound Care Plus, LLC Spotlight Innovation, Sunday 16 October 2022, 11:20 – 12:20, Milan V-VI

b) CLINICAL POSTERS

Manifesto n. PI-026 Fluorescence imaging requires more complete debridement of bacteria and biofilms: real-world data from 1000 wound assessments in 36 states Ashley Jacob *, BSN RN; Laura M. Jones *, PhD; Nathan Krehbiel *, BSN RN; Audrey Moyer-Harris *, BSN RN MBA CWS; Alyssa McAtee, PT, DPT; Isabel Baker, BSN RN, WCC, WHO *; Monique Y. Rennie *, PhD Manifesto here Download

Manifesto n. CR-018 Impact of Fluorescence Imaging of Presence, Location, and Bacterial Burden on Wound Healing, Infections, and Admissions: Retrospective Analysis of 193 Medicare Patient Wounds Martha R. Kelso, RN HBOT Manifesto here Download

Manifesto n. CR-002 Point-of-care fluorescence imaging reveals the extent of chronic inhibitory bacterial burden in diabetic foot ulcers Thomas E. Serena, MD FACS; David Armstrong, DPM MD PhD, Michael E. Edmonds Manifesto here Download

Manifesto n. CR-017 Closing the gap on racial disparities in diagnosing chronic wound infections: the worrying trend involving skin pigmentation and the role of fluorescence imaging Jonathan Johnson, MD MBA CWSP; Alton Johnson Jr., DPM FACPM DABPM CWSP; Charles Andersen, MD FACS; Martha R. Kelso, RN HBOT; Alisha Oropallo, MD FACS; Thomas E. Serena, MD FACS Manifesto here Download

Manifesto n. CR-029 Location matters when sampling a wound – the impact of fluorescence imaging on microbiological findings and its role in diagnostic and antibiotic management Thomas Serena, MD FACS; Philip Bowler, Monique Y. Rennie, PhD Manifesto here Download

Manifesto n. PI-003 The role of bacterial fluorescence scanning in the identification and treatment of intertriginous bacteria in diabetic feet Charles Andersen, MD FACS; Katherine McLeod, RN; Rowena Steffan, RN Manifesto here Download

Manifesto n. PI-002 Incorporating clues from imaging wound dressing into high bacterial load and infection treatment planning Charles Andersen, MD FACS; Katherine McLeod, RN; Rowena Steffan, RN Manifesto here Download

In addition to clinical posters and presentations al SAWC Fall 2022 becomes MolecuLight i: X®- And DX ™ Imaging Devices available for demonstration at MolecuLight booth no. 434 in the Octavius Ballroom (Level 3) at Caesars Palace, Las Vegas, NV.

MolecuLight Imaging Systems I:X® and DX ™ are the only FDA and CE and Health Canada approved imaging devices for real-time detection of high bacterial loads in wounds. With unmatched clinical evidence, including over 60 peer-reviewed publications and 1,500 patients, they are used by leading wound care organizations around the world.

About MolecuLight Inc.

MolecuLight Inc. is a privately held medical imaging company that has developed and commercialized a patented fluorescence imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include MolecuLight fluorescence imaging systems i: X® and DX ™ and its accessories are portable point-of-care imaging devices for the Real-time detection and localization of bacterial load in wounds and the digital wound measurement. MolecuLight procedures performed in the United States benefit from availability discount program. This includes two CPT® codes for the physician’s therapeutic effort to perform a “Fluorescence imaging to determine the presence, location and magnitude of the bacterial load“and a reimbursement for hospital ambulances (H.Hospital oroutpatient D.apartment, HOPD) and outpatient surgical centers (Aoutpatient S.surgical C.log into, ASC) using an APC assignment (Aoutpatient P.ayment C.laxification, APC). The Company is also marketing its unique fluorescence imaging platform technology to other markets around the world with significant and unmet needs for this technique. These include the areas of food safety, consumer cosmetics and other key industrial markets.